Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Randomized, Open-label Study in Japan to Investigate the Efficacy, Safety and Pharmacokinetics of TMC435 as Part of a Treatment Regimen Including Peginterferon Alfa-2a and Ribavirin in Treatment naïve, Genotype 1, Chronic Hepatitis C Subjects
Brief Summary: The purpose of this study is to evaluate effectiveness, safety and pharmacokinetics (Explores what the body does to the medication) of TMC435350 in combination with Peginterferon Alfa-2a and Ribavirin in genotype 1 hepatitis C virus infected Japanese participants who have never received treatment for their hepatitis C infection.


Options:
A: Arm Label: TMC12/PR24 50 mg; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PegIFNα-2a, Drug: RBV | Arm Label: TMC12/PR24 100 mg; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PegIFNα-2a, Drug: RBV | Arm Label: TMC24/PR24 50 mg; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PegIFNα-2a, Drug: RBV | Arm Label: TMC24/PR24 100 mg; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PegIFNα-2a, Drug: RBV | Arm Label: PR48 Control; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: PegIFNα-2a, Drug: RBV | Intervention Type: DRUG; Name: TMC435; Assigned to Arm(s): PR48 Control, TMC12/PR24 100 mg, TMC12/PR24 50 mg, TMC24/PR24 100 mg, TMC24/PR24 50 mg | Intervention Type: DRUG; Name: PegIFNα-2a; Assigned to Arm(s): PR48 Control, TMC12/PR24 100 mg, TMC12/PR24 50 mg, TMC24/PR24 100 mg, TMC24/PR24 50 mg | Intervention Type: DRUG; Name: RBV; Assigned to Arm(s): PR48 Control, TMC12/PR24 100 mg, TMC12/PR24 50 mg, TMC24/PR24 100 mg, TMC24/PR24 50 mg
B: Arm Label: TMC435; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b), Drug: Ribavirin (RBV) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b), Drug: Ribavirin (RBV) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: TMC435; Assigned to Arm(s): TMC435 | Intervention Type: DRUG; Name: Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b); Assigned to Arm(s): Placebo, TMC435 | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): Placebo, TMC435
C: Arm Label: Daclatasvir + Sofosbuvir (Treatment-naive) 12 weeks; Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Sofosbuvir | Arm Label: Daclatasvir + Sofosbuvir (Treatment-naive) 8 weeks; Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Sofosbuvir | Arm Label: Daclatasvir + Sofosbuvir (Treatment-experienced) 12 weeks; Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Sofosbuvir | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir + Sofosbuvir (Treatment-experienced) 12 weeks, Daclatasvir + Sofosbuvir (Treatment-naive) 12 weeks, Daclatasvir + Sofosbuvir (Treatment-naive) 8 weeks | Intervention Type: DRUG; Name: Sofosbuvir; Assigned to Arm(s): Daclatasvir + Sofosbuvir (Treatment-experienced) 12 weeks, Daclatasvir + Sofosbuvir (Treatment-naive) 12 weeks, Daclatasvir + Sofosbuvir (Treatment-naive) 8 weeks
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: danoprevir, Drug: peginterferon alfa-2a [Pegasys], Drug: ribavirin | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: danoprevir, Drug: peginterferon alfa-2a [Pegasys], Drug: ribavirin, Drug: ritonavir | Arm Label: C; Type: PLACEBO_COMPARATOR; Interventions: Drug: peginterferon alfa-2a [Pegasys], Drug: placebo, Drug: ribavirin, Drug: ritonavir | Intervention Type: DRUG; Name: danoprevir; Assigned to Arm(s): A, B | Intervention Type: DRUG; Name: peginterferon alfa-2a [Pegasys]; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): C | Intervention Type: DRUG; Name: ribavirin; Assigned to Arm(s): A, B, C | Intervention Type: DRUG; Name: ritonavir; Assigned to Arm(s): B, C

Answer: A